Vimian Group AB (VIMIAN.ST) stock: key figures, P/E, revenue and dividend

Health Care · Sweden · ISIN SE0015961982

Price
3.54 SEK
Market cap
1.86 bn SEK
P/E (2025)
57.70
P/S (2025)
4.38
Dividend yield
0.00 %
Net margin
7.53 %
Return on equity (ROE)
4.58 %
Return on assets (ROA)
2.88 %

Vimian Group AB financials

Fiscal year20242025
Revenue374.00 m EUR425.00 m EUR
Gross profit258.00 m EUR292.00 m EUR
EBIT53.00 m EUR66.00 m EUR
Net income18.00 m EUR32.00 m EUR
Diluted EPS – continuing operations0.04 EUR0.06 EUR

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 27.10.2026. Details in the risk notice.